Introduction: The goal of chronic hepatitis C
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INTRODUCTION
Hepatitis C virus (HCV) infection represents a significant public health burden, with at least 150 million individuals chronically infected worldwide [1] . The goal of chronic hepatitis C (CHC) treatment is to achieve a sustained virologic response (SVR), which represents HCV clearance to undetectable levels and is considered a ''virologic cure'' [2] . Until 2011 the only available treatment was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of SVR were less than 50%. In 2011 protease inhibitors in combination with PEG/RBV were approved for treatment of genotype 1. While the SVR rates improved to 75-80%, those treatments were associated with high toxicity and poor safety profile [3] . Novel, interferon (INF)-free direct-acting antiviral (DAA) therapies have demonstrated SVR rates of 90-100% and high tolerability in clinical trials [3, 4] . However, access to these agents is generally limited to patients with late-stage disease [5] [6] [7] . As such, it is important to offer a perspective on the consequences of this missed treatment opportunity in a broad range of patients.
This literature review was conducted with the objective of providing a comprehensive review of evidence demonstrating the value of achieving SVR at all stages of liver disease, focusing on four topics: (1) all-cause and liver-related mortality, (2) liver-related morbidity, (3) extrahepatic manifestations (EHMs), and (4) economic impact. The underlying hypothesis is that if HCV affects liver morbidity and EHMs, it should also impact liver-related and all-cause mortality and, ultimately, increase the economic burden of healthcare spending.
METHODS
The feasibility of conducting an original global systematic review was assessed using criteria from the preferred reporting items for systematic reviews and meta-analyses (PRISMA) [8] for the last 10 years. Preliminary searches revealed more than 400 references that potentially met our inclusion criteria (described below). Within these publications, search was further limited to review articles and meta-analyses published between 2006 and January 2016 as well as updates since the last publication date of a review or meta-analysis. However, for the section on EHMs there were no systematic reviews that addressed a comprehensive list of EHMs. Hence, we pooled the references from two recent review articles [9, 10] and conducted additional searches for any recent publications related to the EHMs associated with CHC treatment.
Searches were conducted using the Embase, PubMed, and Cochrane library databases, as well as a review of conference abstracts and general web searches. Inclusion criteria were (1) patients with CHC (excluding special populations such as liver transplant recipients, HIV-HCV co-infected patients, and recurrent or acute HCV cases), (2) retrospective and prospective studies (excluding case report studies), (3) reporting of mortality, liver morbidity, EHM, and economic outcomes, and (4) availability of an abstract or full text from the study publication.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Our search results are summarized in Fig. 1 and size (Table S4 ). We identified seven epidemiological studies on several types of EHMs and 12 publications that studied the impact of SVR on EHMs (Table S5) . Lastly, on the topic of economic value, our search identified four studies on different strategies for treating HCV. We came across one systematic review on the methodology of cost-effectiveness analysis of antiviral therapy.
We leveraged and updated that review to provide a summary of cost-effectiveness publications (Table S6) . Overall, this review summarizes results from 354 studies conducted with more than 500,000 CHC patients worldwide. The studies in each section are summarized in a decreasing order of strength of evidence, meta-analysis followed by prospective and retrospective studies. The authors concluded that the benefits were seen in patients with all stages of liver fibrosis, and the effects were significant even in advanced fibrosis stages [12] .
Survival Benefit of SVR
A meta-analysis of 26 studies (n = 15,621) 
Studies Estimating Broad Prevalence of EHMs
A recent meta-analysis of 69 studies estimated the overall burden of seven EHMs due to HCV (Table S3 ). In this analysis the pooled prevalence estimate of MC (n = 14 studies) was 32% in the HCV group (95% CI 21-43%) and 3% (95% CI 0-8%) in the non-HCV group (n = 3 studies). The pooled prevalence of diabetes mellitus (DM) (n = 16 studies) among HCV patients was 15%
(95% CI 13-18%) compared to 10% (95% CI 4-15%) in the non-HCV population. The pooled odds ratio (OR) of developing chronic kidney disease/end-stage renal disease (CKD/ESRD) in patients with HCV compared to the non-HCV group (n = 11 studies) was 1.29 (95% CI 1.13-1.45). The risk of lymphoma was 64%
higher (OR 1.64; 95% CI 1.18-2.11) in patients with HCV compared to the non-HCV population. The pooled prevalence estimate of lichen planus among HCV (n = 11 studies) was 2.1% (95% CI 1.1-3.1%) while the prevalence in non-HCV (n = 3 studies) was 1.4% (95% CI 0-3.4%). The pooled prevalence of Sjögren's syndrome (n = 6 studies) was 1.11% (95% CI 0.17-0.53%) compared to 0.11% (95% CI 0.09-0.13%) in the non-HCV group (n = 1 study). The pooled prevalence of porphyria cutanea tarda (PCT) among HCV patients (n = 5) was 0.7% (95% CI 0.2-1.1%) whereas the prevalence in the non-HCV group (n = 1 study) was 0.06% (95% CI 0.05-0.07) [14] .
Globally, a relatively significant prevalence of EHMs has been found in CHC patients in five retrospective studies conducted in Italy (n = 440), Poland (n = 340), China (n = 297), Romania (n = 162), and Turkey (n = 62) [29-33].
Studies on Specific EHMs
Mixed Cryoglobulinemia (MC) 
Renal Insufficiency
In a retrospective study of patients in the US Veteran Affairs healthcare system (n = 1928 HCV antibody positive and n = 23,854 HCV antibody negative), after adjustment for age, race, gender, diabetes, and hypertension, HCV-positive veterans had a 40% higher odds for renal insufficiency (odds ratio 1.40; 95% CI 1.11-1.76) as compared with HCV-negative veterans [45] .
A large-scale community study (n = 54,966) on the effect of viral hepatitis (HCV or HBV) on nephropathy in Taiwan found that HCV infection alone (OR 1.26; 95% CI 1.17-1.38) was an independent risk factor for CKD, but not HBV infection alone or HBV/HCV coinfection [46] .
Cardiovascular Disorders
A meta-analysis of six studies showed a strong link between HCV and risk of stroke, with 22,171 HCV-infected individuals and 87,418 controls, and an estimated pooled OR of 1.58 (0.86, 2.30) [47] . Similarly, high risk of stroke was observed in a large retrospective database study in Taiwan (n = 4084 HCV and n = 16,376 controls), with a cumulative risk of stroke for people with and without HCV of 2.5% and 1.9%, respectively (p\0.0001). Compared to people without HCV, the adjusted HR of stroke was 1.27 (95% CI 1.14-1.41) for people with HCV [48] .
A strong link between HCV and coronary artery disease (CAD) was observed in a large database study of US Veteran Affairs patients (n = 82,083 HCV-infected and n = 89,582 HCV-uninfected). The study showed that HCV infection was associated with a higher risk of 
Studies on Value of Antiviral Therapy in Patients with HCV-Related EHMs
In our review we found 15 studies (n = 12,974), which have demonstrated value of antiviral therapy in lowering the burden of EHMs in CHC patients (Table S4) The model showed that a 2-year delay in treatment could reduce the impact of disease burden control efforts by 10%, while a 5-year delay could reduce the impact by 30% [61] . The authors concluded that a substantial reduction in disease burden could be achieved by means of both higher efficacy drugs and increased treatment uptake, underscoring the importance of comprehensive treatment with INF-free DAA therapies [62] .
DISCUSSION
In our review of the literature we found a large body of evidence demonstrating diverse sources of value for CHC patients achieving SVR in all stages of liver disease. Overall, this review summarizes results from 354 studies conducted in more than 500,000 patients. The summarized evidence confirms our hypothesis that HCV affects liver morbidity and EHMs, which leads to increased liver-related and all-cause mortality and high economic burden. The evidence also strongly demonstrates that achievement of SVR can increase survival, reduce liver and extrahepatic morbidity, and lower long-term costs. Even unsuccessful CHC treatment appears to have a protective effect against mortality and liver morbidity. In 2013, when INF-free DAAs were licensed, Georgia engaged partners to develop a national HCV prevention and control plan targeting the elimination of HCV transmission and disease [63] . Similarly, the Hepatitis Prevention, Control, and Elimination (HPCE) Program was officially launched in September 2014 to radically change the current state of viral hepatitis in Mongolia and significantly reduce the disproportionate and sustained burden of liver cirrhosis, liver cancer, and mortality [64] . In Egypt, the government has launched a comprehensive HCV treatment program with a goal to treat 300,000 people a year (WHO 2015). In these exemplary cases, a strong healthcare infrastructure and political will are crucial to battle HCV by implementing effective screening and treatment programs [65] . In Australia, the federal government has announced that it will subsidize new breakthrough HCV treatments to cure all patients [66] . The implementation and outcomes of these programs should be closely monitored as they could provide valuable real-world policy lessons for other regions. Recently, the French government announced plans to provide universal access to new HCV medications [67] .
The demonstrated value of achieving SVR underscores the importance of comprehensive treatment strategies targeting all stages of liver disease and based on the most effective and tolerable class of DAA regimens. It should be further noted that the majority of the studies summarized here were conducted with INF-based antivirals which had relatively low cure rates and high toxicity. The new generation of DAAs offer 90-100% cure rates and have a significantly better safety profile, making the case even stronger to offer these treatment options to patients in all stages of liver disease [3] .
There are some limitations of our review. As a result of the broad scope of the topic and robust body of evidence it was not possible to conduct a full systematic review. However, to provide a summary on relevant topics we leveraged the highest-quality evidence such as meta-analyses and systematic reviews. 
